Subcutaneous anifrolumab is superior to placebo in multiple systemic lupus erythematosus disease activity measures at 52 ...
Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
The FDA has issued a complete response letter to AstraZeneca regarding its application for subcutaneous administration of ...
AstraZeneca announces update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus: Cambridge, UK Wednesday, February 4, 2026, 16:00 Hrs ...
Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.
The TULIP-SC trial evaluated the efficacy and safety of the subcutaneous administration of SAPHNELO compared to placebo in participants with moderately to severely active, autoantibody-positive SLE, ...
Please provide your email address to receive an email when new articles are posted on . DENVER — Subcutaneous administration of ocrelizumab showed similar safety and efficacy profiles to IV ...
The company is working with the U.S. regulator to move forward with an updated application, adding a decision is expected in ...
February 2026 Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus The US Food and Drug Administration (FDA) issued a complete response letter (CRL) ...
The US Food and Drug Administration rejected a subcutaneous version of AstraZeneca Plc’s lupus medicine that would make it easier to administer.
Many professionals report awareness, but few actively prescribe the self-administered injectable contraceptive DMPA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results